NewsBenzingaJazz Pharmaceuticals Presents Data From Its Phase 3 HERIZON-GEA-01 Study Of Ziihera In Combination With Chemotherapy At ESMO Congress 2026 To Treat Patients With HER2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma Jazz Pharmaceuticals Presents Data From Its Phase 3 HERIZON-GEA-01 Study Of Ziihera In Combination With Chemotherapy At ESMO Congress 2026 To Treat Patients With HER2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma Benzinga 2026.10.23 14:20 (GMT+0) Open on Benzinga Other news IBM Stock Moves Lower: What's Going On? JP Morgan Maintains Overweight on Itau Unibanco Holding, Lowers Price Target to $9 Amazon’s Big Week: First a New James Bond, Then Anthropic’s IPO JP Morgan Maintains Overweight on Allstate, Lowers Price Target to $291 TELUS Shares Rise After Québecor Submits Unsolicited Acquisition Proposal NVIDIA's Leadership Vacuum Hands AMD Its Biggest Opportunity in Years: Analysts